Business Context and Reporting Period
This Form 8-K Current Report was filed by CG Oncology, Inc. on September 5, 2025. The filing primarily serves as a Regulation FD disclosure and report of other events regarding updated clinical trial data for the company's investigational therapy, cretostimogene.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements or operational financial data.
Material Changes and Clinical Data
The company reported updated data from Cohort C of the BOND-003 Phase 3 clinical trial evaluating cretostimogene as monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Key data points as of the June 23, 2025 cutoff include:
- Complete Response (CR) at 24 Months: 41.8% (46 out of 110 patients), with 12 additional patients achieving CR at this landmark.
- Overall CR Rate: 75.5% of patients achieved CR at any time.
- Duration of Response (DOR): Estimated rates are 64.1% at 12 months and 58.3% at 24 months. Median DOR is 28 months and ongoing.
- Disease Progression: 96.6% of patients were free from progression to muscle invasive disease at 24 months.
- Safety Profile: No Grade 3 or greater treatment-related adverse events (TRAEs) or deaths were reported. No treatment-related discontinuations occurred, and 97.3% of patients completed all expected treatments.
- Common Adverse Events: Bladder spasm, pollakiuria, micturition urgency, dysuria, and hematuria (all occurring in ≥10% of patients).
Guidance, Outlook, and Risks
Management commentary emphasizes that the data reaffirms the "best-in-disease durability and tolerability" of cretostimogene. The company posted an updated corporate presentation on its website but noted it does not intend to file future 8-Ks for presentation updates.
Risks and Contingencies: The filing includes standard forward-looking statement disclaimers. Risks include:
- Future patient data may be inconsistent with current results.
- Potential for unexpected adverse side effects or inadequate efficacy.
- Delays in clinical trial commencement, enrollment, or completion.
- Competitive developments affecting commercial opportunities.
Investor Verification Checklist
- Verify the full text of the press release attached as Exhibit 99.1 for detailed statistical tables.
- Review the updated corporate presentation on the company's Investor Relations website for broader context.
- Consult the most recent Form 10-Q (ended June 30, 2025) and Form 10-K for financial health and detailed risk factors not included in this 8-K.
- Monitor future filings for any changes in the clinical trial timeline or regulatory submission plans.